Episode Details

Back to Episodes
Is more clarity needed in the HSE's drugs group decision making?

Is more clarity needed in the HSE's drugs group decision making?

Published 1 week, 1 day ago
Description

The HSE drugs group’s recommendation to refuse reimbursement for the drug Skyclarys is a stark reminder of the devastating human cost that can lie behind bureaucratic decisions. So wrote Consultant in Paediatric Intensive Care, Dr Suzanne Crowe, in The Journal yesterday.

She joins Ciara to discuss.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us